GTBP Kacepetan wutah bathi saben saham ing taun lumaku GT Biopharma Corporation

Lambang korporat lan logo gtbiopharma.com (GTBP)

The monetization of immune platforms creates a foundation for future royalties from pharma behemoths for GT Biopharma, Inc. (GTBP). Annual EPS fluctuations highlight this potential, where the 0.00 level captures fresh values. Growth is driven by the digitalization of screening via AI and TriKE systems. The current development vector relies on early safety tests of new NK-cell inductors to attract strategic partners.

GTBP - Wutah bathi ing taun lumaku GT Biopharma ing rentang 04.07.2022 - 16.11.2026

Rincian metrik komprehensif lan analitis GT Biopharma (GTBP)

- nilai saham lan prakiraan konsensus rega:
Pambiji fundamental:GT Biopharma Corp, GTBP
Barang unggulan gtbiopharma.com

This metric is calculated as the percentage deviation of current earnings per share from the value of the same period last year, reflecting the dynamics of return on equity. Growth in this metric signals effective asset monetization, which for GT Biopharma, Inc. (GTBP) depends directly on the success of the TriKE platform clinical trials in leukemia therapy. By analyzing the relative change in EPS compared to the same period last year, an investor can assess the fundamental stability of the company.